SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Babe Didrikson Zaharias — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientMildred Ella Didrikson Zaharias
Date of birth1911-06-26
IdentifiersMRN HR-ML038-SYN-TD; SSN (made up) 000-38-4471
Document date1953-03-30
AuthorRosalind Vasquez-Thornbury, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Diagnosis visit: biopsy and staging results, the tumor board plan, and the oncology and surgical consultations. [S]

History of Present Illness

Ms. Didrikson Zaharias returns two weeks after her first visit. Colonoscopy three days after that visit found an ulcerated mass in the lower rectum, from 4 to 9 cm from the anal verge, and nothing else in the colon; the biopsies show adenocarcinoma, and the tumor has lost the mismatch repair proteins MSH2 and MSH6 and is microsatellite instability high. Rectal-protocol MRI shows a tumor whose lower edge is about 1 cm above the anorectal junction, growing just through the bowel wall, with two suspicious lymph nodes and a clear mesorectal fascia (cT3bN1). CT of the chest, abdomen and pelvis shows no spread. The tumor board met three days ago. She was seen today by Dr. Albright-Nakamura and by the colorectal surgeon, who explained that surgery for a tumor this low would most likely mean removing the rectum and anus with a permanent colostomy. She still passes some bright red blood most days, less than before, and feels tired on the back nine. Her first question was whether she would need a bag; her second was whether she could keep playing. [S]

ElementDetail
DiagnosisLow rectal adenocarcinoma, mismatch repair deficient (loss of MSH2 and MSH6), cT3bN1M0, stage IIIB
Procedures since the first visitColonoscopy with biopsy; rectal-protocol MRI of the pelvis; CT of the chest, abdomen and pelvis; tumor board
Tumor boardDostarlimab every three weeks for six months, restaging about every three months, and watch-and-wait if the response is complete; chemoradiation and surgery in reserve
SymptomsLess bleeding; still some urgency; tired late in a round
Her questionsWhether she will need a bag; whether she can keep competing; what the genetic test means for her brothers and sisters

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired late in a round; weight 62.6 kg, steady; no fever
GastrointestinalPositiveBright red blood on most days, less than before; urgency; narrow stools
GenitourinaryPositivePain during sex and spotting afterwards; no urinary symptoms
CardiovascularNegativeNo palpitations, fainting or leg swelling
MusculoskeletalNegativeNo back or pelvic pain
PsychiatricPositiveFrightened by the word cancer and determined; PHQ-9 6, GAD-7 7; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morningOne tablet every other morningOral route1953-03-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1953-03-30Body height168cmS
1953-03-30Body weight62.6kgS
1953-03-30Body mass index (BMI) [Ratio]22.2kg/m2S
1953-03-30Systolic blood pressure116mm[Hg]S
1953-03-30Diastolic blood pressure72mm[Hg]S
1953-03-30Heart rate80/minS
1953-03-30Respiratory rate14/minS
1953-03-30Body temperature36.6CelS
1953-03-30Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1953-03-30Hemoglobin [Mass/volume] in Blood11.1g/dL12-15.5 g/dLLowS
1953-03-30Leukocytes [#/volume] in Blood by Automated count6.510*3/uL4-11 10*3/uLNormalS
1953-03-30Platelets [#/volume] in Blood by Automated count40510*3/uL150-400 10*3/uLHighS
1953-03-30Creatinine [Mass/volume] in Serum or Plasma0.76mg/dL0.59-1.04 mg/dLNormalS
1953-03-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1948)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1953-03-30Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
1953-03-30Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma17U/L7-35 U/LNormalS
1953-03-30Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L8-35 U/LNormalS
1953-03-30Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
1953-03-30Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
1953-03-30Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1953-03-30Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S

Physical Exam

Vital signs recorded on 1953-03-30; see the Vital Signs section. [S]

SystemFinding
GeneralFit, tanned, composed; weight 62.6 kg; blood pressure 116/72, pulse 80
AbdomenSoft, non-tender; no liver enlargement or mass
Lymph nodesNo inguinal or supraclavicular nodes
RectalWith her agreement and a chaperone: firm, ulcerated, partly mobile mass on the posterior and left wall, lower edge about 4 to 5 cm from the anal verge; sphincter tone normal; blood on the glove
PsychiatricDirect and focused; asks exact questions about her game and about a colostomy

Problems

ProblemClinical statusVerificationCodeProvenance
Bright red blood with bowel movements for about three months, with narrower stools, urgency, a feeling of incomplete emptying, and a firm, ulcerated mass felt on the back wall of the lower rectum at about 5 cm from the anal verge: a rectal cancer must be confirmed or excluded. Colonoscopy with biopsy booked this weekresolvedconfirmed K62.5S — Synthetic presenting problem anchored to the documented fatigue before her cancer diagnosis. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic rectal blood loss: hemoglobin 11.0 g/dL, MCV 77 fL, ferritin 9 ng/mL, with tirednessactiveconfirmed D50.0S — Synthetic finding anchored to the documented fatigue at the end of the 1952 season.
Adenocarcinoma of the low rectum, mismatch repair deficient (loss of MSH2 and MSH6; microsatellite instability high), cT3bN1M0 (stage IIIB) on pelvic MRI, lower edge 4 cm from the anal verge and about 1 cm above the anorectal junction, mesorectal fascia clear, no extramural venous invasion; CEA 5.8 ng/mL; synthetic modern detail linked to her documented cancer, whose site the sources do not record exactlyactiveconfirmed C20S — Synthetic histology, site, stage, mismatch repair status and course; the sources say she had cancer treated with a colostomy and call it colon cancer (R on the site). See sources.md.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryTissue diagnosis and mismatch repair testingBefore treatment; mismatch repair testing for every colorectal cancerUp to dateAdenocarcinoma, moderately differentiated; loss of MSH2 and MSH6 on immunohistochemistry; microsatellite instability high
ImagingRectal-protocol MRI of the pelvisAt diagnosis, before any treatmentUp to datecT3b, two suspicious mesorectal nodes (cN1), mesorectal fascia clear by 6 mm, no extramural venous invasion, lower edge about 1 cm above the anorectal junction
ImagingCT of the chest, abdomen and pelvisAt diagnosisUp to dateNo metastases
ReferralMultidisciplinary tumor boardBefore treatment for every rectal cancerUp to dateThree days ago: dostarlimab, restaging, watch-and-wait if complete response
ReferralColorectal surgery consultationBefore treatment of every rectal cancerCompleted todaySeen today: surgery now would most likely be abdominoperineal resection with a permanent colostomy; surgery kept in reserve for an incomplete response or regrowth
ReferralWound-ostomy nursing: stoma site marking and teachingBefore any operation that may create a stomaNot indicatedNo operation planned; to be arranged at once if surgery becomes necessary
LaboratoryCEAAt diagnosis, at each restaging, then every three to six months for two yearsUp to date5.8 ng/mL at the first visit; next with restaging
ExaminationDigital rectal examinationAt each oncology visit during treatment; every three to four months in watch-and-waitCompleted todayLower edge about 4 to 5 cm from the anal verge; sphincter tone normal
LaboratoryBlood countBefore each dose of dostarlimab and at each visit; about four weeks after oral iron startsCompleted todayHemoglobin 11.1 g/dL, white cells 6.5, platelets 405
LaboratoryKidney and liver function and glucoseAt baseline and before each dose of PD-1 blockadeCompleted todayCreatinine 0.76 mg/dL, eGFR 101; ALT 17 U/L, AST 20 U/L; glucose 90 mg/dL
LaboratoryTSH and free T4At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine changeCompleted todayBaseline TSH 1.9 mIU/L, free T4 1.2 ng/dL
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore systemic cancer treatmentOrderedHepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV drawn today
LaboratoryPregnancy testBefore treatmentCompleted todayUrine pregnancy test negative
Medication safetyContraception during PD-1 blockadeThroughout treatment and for four months after the last doseUp to dateLevonorgestrel intrauterine device in place
LaboratoryGermline multigene panelFor every colorectal cancer diagnosed under 50 and every mismatch repair-deficient tumorOrderedSent today after counseling
ReferralGenetic counselingBefore germline testingCompleted todayPedigree as she knows it; she knows of no relative with a Lynch-associated cancer; consent for testing
Self-managementTeaching about immune-related adverse eventsBefore the first doseCompleted todayWritten guide and 24-hour line: report diarrhea, blood in the stool, rash, cough, breathlessness, unusual tiredness, headache or thirst
SurveyDistress and depression screen (PHQ-9, GAD-7)At diagnosis, at each treatment phase, and at least yearlyCompleted todayPHQ-9 6 (item 9 scored 0), GAD-7 7
Self-managementSexual health and body imageAt diagnosis and through treatmentCompleted todayPain and spotting after sex explained by the tumor; told they should settle as it responds; a lubricant meanwhile
Self-managementPhysical activity and sportEach visitCompleted todayEncouraged to keep playing and training as she feels able; no restriction from dostarlimab

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol 2024;42(28):3355-3375 (PMID 39116386) (2024); Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022); Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Tung N, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol 2024;42(21):2599-2615 (PMID 38759122) (2024); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026)

Follow-up: Dostarlimab cycle 1 next week. Primary care review at cycle 2. Call at once for heavy bleeding, fainting, diarrhea, rash, cough or breathlessness. Next scheduled visit 1953-04-27: day 1 of cycle 2 of dostarlimab: early response, immune-related adverse event checks, germline and tumor genetic results, iron and anemia, and golf. [S]